
    
      Scheme:

      Eligible fosaprepitant sensitive (complete response [defined as no emesis and no use of
      rescue antiemetics] during the overall phase [0 to 120 hours] of all cycles of
      cisplatin-based induction chemotherapy) NPC patients will be randomized to 2 arms at 1:1
      ratio.

        -  Weekly Arm: fosaprepitant 150mg/m2 weekly in concurrent with radiotherapy during
           concurrent chemoradiotherapy.

        -  Triweekly Arm: fosaprepitant 150mg/m2 triweekly in concurrent with chemotherapy during
           concurrent chemoradiotherapy.
    
  